These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 37219717)
21. Maximum Uptake and Hypermetabolic Volume of 18F-FDOPA PET Estimate Molecular Status and Overall Survival in Low-Grade Gliomas: A PET and MRI Study. Tatekawa H; Yao J; Oughourlian TC; Hagiwara A; Wang C; Raymond C; Lai A; Cloughesy TF; Nghiemphu PL; Liau LM; Salamon N; Ellingson BM Clin Nucl Med; 2020 Dec; 45(12):e505-e511. PubMed ID: 33031233 [TBL] [Abstract][Full Text] [Related]
22. Molecular Subtype Classification in Lower-Grade Glioma with Accelerated DTI. Aliotta E; Nourzadeh H; Batchala PP; Schiff D; Lopes MB; Druzgal JT; Mukherjee S; Patel SH AJNR Am J Neuroradiol; 2019 Sep; 40(9):1458-1463. PubMed ID: 31413006 [TBL] [Abstract][Full Text] [Related]
23. Apparent diffusion coefficient for molecular subtyping of non-gadolinium-enhancing WHO grade II/III glioma: volumetric segmentation versus two-dimensional region of interest analysis. Thust SC; Hassanein S; Bisdas S; Rees JH; Hyare H; Maynard JA; Brandner S; Tur C; Jäger HR; Yousry TA; Mancini L Eur Radiol; 2018 Sep; 28(9):3779-3788. PubMed ID: 29572636 [TBL] [Abstract][Full Text] [Related]
24. Multiparametric MR-PET measurements in hypermetabolic regions reflect differences in molecular status and tumor grade in treatment-naïve diffuse gliomas. Tatekawa H; Hagiwara A; Uetani H; Yao J; Oughourlian TC; Bahri S; Wang C; Raymond C; Lai A; Cloughesy TF; Nghiemphu PL; Liau LM; Pope WB; Salamon N; Ellingson BM J Neurooncol; 2020 Sep; 149(2):337-346. PubMed ID: 32929644 [TBL] [Abstract][Full Text] [Related]
25. Regional and Volumetric Parameters for Diffusion-Weighted WHO Grade II and III Glioma Genotyping: A Method Comparison. Thust SC; Maynard JA; Benenati M; Wastling SJ; Mancini L; Jaunmuktane Z; Brandner S; Jäger HR AJNR Am J Neuroradiol; 2021 Mar; 42(3):441-447. PubMed ID: 33414227 [TBL] [Abstract][Full Text] [Related]
26. Diagnostic performance of gliomas grading and IDH status decoding A comparison between 3D amide proton transfer APT and four diffusion-weighted MRI models. Guo H; Liu J; Hu J; Zhang H; Zhao W; Gao M; Zhang Y; Yang G; Cui Y J Magn Reson Imaging; 2022 Dec; 56(6):1834-1844. PubMed ID: 35488516 [TBL] [Abstract][Full Text] [Related]
27. MRI Features and IDH Mutational Status of Grade II Diffuse Gliomas: Impact on Diagnosis and Prognosis. Villanueva-Meyer JE; Wood MD; Choi BS; Mabray MC; Butowski NA; Tihan T; Cha S AJR Am J Roentgenol; 2018 Mar; 210(3):621-628. PubMed ID: 29261348 [TBL] [Abstract][Full Text] [Related]
28. Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors. Malzkorn B; Reifenberger G Pathologe; 2019 Jun; 40(Suppl 1):9-17. PubMed ID: 31025086 [TBL] [Abstract][Full Text] [Related]
29. Integration of dynamic parameters in the analysis of Ginet M; Zaragori T; Marie PY; Roch V; Gauchotte G; Rech F; Blonski M; Lamiral Z; Taillandier L; Imbert L; Verger A Eur J Nucl Med Mol Imaging; 2020 Jun; 47(6):1381-1390. PubMed ID: 31529264 [TBL] [Abstract][Full Text] [Related]
30. Clinical significance of the 2016 WHO classification in Japanese patients with gliomas. Iuchi T; Sugiyama T; Ohira M; Kageyama H; Yokoi S; Sakaida T; Hasegawa Y; Setoguchi T; Itami M Brain Tumor Pathol; 2018 Apr; 35(2):71-80. PubMed ID: 29470683 [TBL] [Abstract][Full Text] [Related]
31. Prediction of TERTp-mutation status in IDH-wildtype high-grade gliomas using pre-treatment dynamic [ Li Z; Kaiser L; Holzgreve A; Ruf VC; Suchorska B; Wenter V; Quach S; Herms J; Bartenstein P; Tonn JC; Unterrainer M; Albert NL Eur J Nucl Med Mol Imaging; 2021 Dec; 48(13):4415-4425. PubMed ID: 34490493 [TBL] [Abstract][Full Text] [Related]
32. Exploring the mechanism of 18F-fluorodopa uptake in recurrent high-grade gliomas: A comprehensive histomolecular-positron emission tomography analysis. Cobes N; Tran S; Mathon B; Nichelli L; Bielle F; Touat M; Kas A; Rozenblum L Eur J Neurol; 2024 Jan; 31(1):e16093. PubMed ID: 37823694 [TBL] [Abstract][Full Text] [Related]
33. MR textural analysis on T Rui W; Ren Y; Wang Y; Gao X; Xu X; Yao Z J Magn Reson Imaging; 2018 Jul; 48(1):74-83. PubMed ID: 29140606 [TBL] [Abstract][Full Text] [Related]
34. Prediction of IDH Mutation Status in High-grade Gliomas Using DWI and High T1-weight DSC-MRI. Cindil E; Sendur HN; Cerit MN; Erdogan N; Celebi F; Dag N; Celtikci E; Inan A; Oner Y; Tali T Acad Radiol; 2022 Mar; 29 Suppl 3():S52-S62. PubMed ID: 33685792 [TBL] [Abstract][Full Text] [Related]
35. Evaluation of Key Molecular Markers in Adult Diffuse Gliomas Based on a Novel Combination of Diffusion and Perfusion MRI and MR Spectroscopy. Su X; Yang X; Sun H; Liu Y; Chen N; Li S; Huang Z; Shao H; Zhang S; Gong Q; Yue Q J Magn Reson Imaging; 2024 Feb; 59(2):628-638. PubMed ID: 37246748 [TBL] [Abstract][Full Text] [Related]
36. Zhao K; Yu P; Xue Z; Liu J; Yao A; Zhao Y; Yang F; Tian J; Xu B Acad Radiol; 2020 Jul; 27(7):e159-e167. PubMed ID: 31607471 [TBL] [Abstract][Full Text] [Related]
37. MR Imaging-derived Oxygen Metabolism and Neovascularization Characterization for Grading and IDH Gene Mutation Detection of Gliomas. Stadlbauer A; Zimmermann M; Kitzwögerer M; Oberndorfer S; Rössler K; Dörfler A; Buchfelder M; Heinz G Radiology; 2017 Jun; 283(3):799-809. PubMed ID: 27982759 [TBL] [Abstract][Full Text] [Related]
38. TSPO PET, tumour grading and molecular genetics in histologically verified glioma: a correlative Unterrainer M; Fleischmann DF; Vettermann F; Ruf V; Kaiser L; Nelwan D; Lindner S; Brendel M; Wenter V; Stöcklein S; Herms J; Milenkovic VM; Rupprecht R; Tonn JC; Belka C; Bartenstein P; Niyazi M; Albert NL Eur J Nucl Med Mol Imaging; 2020 Jun; 47(6):1368-1380. PubMed ID: 31486876 [TBL] [Abstract][Full Text] [Related]
39. IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein-specific PET/CT. Röhrich M; Loktev A; Wefers AK; Altmann A; Paech D; Adeberg S; Windisch P; Hielscher T; Flechsig P; Floca R; Leitz D; Schuster JP; Huber PE; Debus J; von Deimling A; Lindner T; Haberkorn U Eur J Nucl Med Mol Imaging; 2019 Nov; 46(12):2569-2580. PubMed ID: 31388723 [TBL] [Abstract][Full Text] [Related]